Expert View

1.    Tong XW, Block A, Chen SH, Contant CF, Agoulnik I, Blankenburg K, Kaufman RH, Woo SL, Kieback DG, In vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration. Gynecol Oncol  61: 2, 175-9, May, 1996.

2.    Kent-First MG, Maffitt M, Muallem A, Brisco P, Shultz J, Ekenberg S, Agulnik AI, Agoulnik I, Shramm D, Bavister B, Abdul-Mawgood A, VandeBerg J, Gene sequence and evolutionary conservation of human SMCY, Nat Genet 14: 2, 128-9, Oct, 1996.

3.    Tong XW, Agoulnik I, Blankenburg K, Contant CF, Hasenburg A, Runnebaum LB, Stickeler E, Kaplan AL, Woo SL, Kieback DG, Human epithelial ovarian cancer xenotransplants into nude mice can be cured by adenovirus-mediated thymidine kinase gene therapy., Anticancer Res 17: 2A, 811-3, Mar-Apr, 1997.

4.    Agoulnik IU, Cho Y, Niederberger C, Kieback DG, Cooney AJ, Cloning, expression analysis and chromosomal localization of the human nuclear receptor gene GCNF., FEBS Let 424: 1-2, 73-8, Mar 6, 1998.

5.    Tong XW, Engehausen DG, Kaufman RH, Agoulnik I, Contant C, Freund CT, Oehler MK, Kim TE, Hasenburg A, Woo SL, Kieback DG, Improvement of gene therapy for ovarian cancer by using acyclovir instead of ganciclovir in adenovirus mediated thymidine kinase gene therapy., Anticancer Res 18: 2A, 713-8, Mar-Apr, 1998.

6.    Tong X, Engehausen DG, Freund CT, Agoulnik I, Guo Z, Oehler MK, Kim TE, Hasenburg A, Contant CF, Woo SL, Kieback DG, The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter., Anticancer Res 18: 2A, 719-25, Mar-Apr, 1998.

7.    Levy T, Agoulnik I, Atkinson EN, Tong XW, Gause HM, Hasenburg A, Runnebaum IB, Stickeler E, Mobus VJ, Kaplan AL, Kieback DG, Telomere length in human white blood cells remains constant with age and is shorter in breast cancer patients., Anticancer Res 18: 3A, 1345-9, May-Jun, 1998.

8.    Tong X, Shine DH, Agoulnik I, Freund CT, Hasenburg A, Aguilar-Cordova E, Woo SL, Kieback DG, Adenovirus mediated thymidine kinase gene therapy may enhance sensitivity of ovariancancer cells to chemotherapeutic agents. Anticancer Res 18:5A, 3421-6, Sep-Oct, 1998.

9.  Tong X, Engehausen DG, Freund CT, Agoulnik I, Oehler MK, Kim TE, Hasenburg A, Guo Z, Contant CF, Woo SL, Kieback DG, Comparison of long-term survival of cytomegalovirus promotre versus Rous Sarcoma virus promoter-driven thymidine kinase gene therapy in nude mice bearing human ovarian cancer. Hybridoma 18:1, 93-7, Feb, 1999.

10.  Bishop CE, Whitworth DJ, Qin Y, Agoulnik AI, Agoulnik IU, Harrison WR, Behringer RR, Overbeek PA, A transgenic insertion upstream of sox9 is associated with dominant XX sex reversal in the mouse. Nat Genet 26:4, 490-4 Dec, 2000.

11.  James AJ, Agoulnik IU, Harris JM, Buchanan G, Tilley WD, Marcelli M, Lamb DJ, Weigel NL, A Novel Androgen Receptor Mutant, A748T, Exhibits Hormone Concentration-Dependent Defects in Nuclear Accumulation and Activity Despite Normal Hormone-Binding Affinity., Mol Endocrinol 16:12, 2692-705 Dec, 2002

12.  Weigel NL and Agoulnik IU (2003) Steroid Receptor Crosstalk with Cellular Signalling Pathways. Encyclopedia of hormones Academic Press. Elsevier Science

13.  Koshkina NV, Agoulnik IU, Melton SL, Densmore CL, Knight V (2003) Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes:optimization of pulmonary delivery and retention. Molecular Therapy 8:2; 249-54 Aug, 2003

14.  Agoulnik IU, Krause WC, Bingman WE 3rd, Rahman HT, Amrikachi M, Ayala GE, Weigel NL (2003) Repressors of androgen and progesterone receptor action. J Biol Chem 278:33; 31136-48 Aug, 2003

15.  Agoulnik IU, Tong XW, Fischer DC, Koerner K, Atkinson NE, Edwards DP, Headon DR, Weigel NL, Kieback DG (2004) A Germline Variation in the Progesterone Receptor Gene Increases Transcriptional Activity and May Modify Ovarian Cancer Risk. The Journal of Clinical Endocrinology & Metabolism 89:12; Dec, 2004

16.  Murthy S, Agoulnik IU,  Weigel NL. Androgen Receptor Signaling and Vitamin D Receptor Action in Prostate Cancer Cells. Prostate. 1:64;362-72 Sep, 2005

17.  Agoulnik IU, Vaid A, Bingman WE III, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. A Role for SRC-1 in Promoting Prostate Cancer Cell Growth and Tumor Progression. Cancer Research. 1:65;7959-67 2005 Sep, 2005

18.  Dai H, Li R, Wheeler T, de Vivar AD, Chen X, Frolov A, Agoulnik IU, Thompson T, Rowley D, Ayala G. Pim-2 Upregulation: Biological Implications Associated with Perinueral Invasion and Disease Progression in Prostate Cancer. Prostate. 1:65;276-86 Nov, 2005

19.  Kamat AA, Feng S, Agoulnik IU, Kheradmand F, Bogatcheva NV, Coffey D, Sood AK, Agoulnik AI. The Role of Relaxin in Endometrial Cancer. Cancer Biol Ther. 31:5; 71-7 Jan, 2006

20.  Marcelli M, Stenoien DL, Szafran AT, Simeoni S, Agoulnik IU, Weigel NL, Moran T, Mikic I, Price JH, Mancini MA. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem. 98:4; 770-88 Jan, 2006

21.  Agoulnik IU, Weigel NL. Androgen Receptor Action in Androgen Dependent and Recurrent Prostate Cancer. J Cell Biochem. 99:2;362-72 Oct, 2006

22.  Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE III, Erdem H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. Androgen Receptor Coactivator TIF2 Expression, Biochemical Recurrence and Androgen Independence of Prostate Cancer. Cancer Research. 66:21; 10594-602 Nov, 2006

23.  Agoulnik IU, Weigel NL. Androgen Receptor Coactivators and Prostate Cancer. Hormonal Carcinogenesis, Volume V. 5^th International Symposium on Hormonal Carcinogenesis. 2006

24.  Feng S, Agoulnik IU, Bogatcheva NV, Kamat AA, Kwabi-Addo B, Li R, Ayala G, Ittmann MM, Agoulnik AI. Relaxin promotes prostate cancer progression. Clin Cancer Res, 13:6;1695-702 March, 2007.

25.  Feng S, Bogatcheva NV, Truong A, Korchin B, Bishop CE, Klonisch T, Agoulnik IU, Agoulnik AI. Developmental expression and gene regulation of insulin-like 3 receptor RXFP2 in mouse male reproductive organs. Biol Reprod, 77:4;671-80. Oct, 2007.

26.  Agoulnik IU, Weigel NL. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol, 617:245-55. 2008

27.  Agoulnik IU, Nakka M, Weigel NL. Target Gene Specific Regulation of Androgen Receptor Activity by p42/p44 MAPK. Mol Endo, 22(11):2420-32. Nov, 2008.

28.  Feng S, Agoulnik IU, Li Z, Han HD, Lopez-Berestein G, Sood A, Ittmann MM, Agoulnik AI. Relaxin/RXFP1 signaling in prostate cancer progression. Ann N Y Acad Sci. 1160:379-80. Apr, 2009.

29.  Li Z, Burzawa JK, Troung A, Feng S, Agoulnik IU, Tong X, Anderson ML, Kovanci E, Rajkovic A, Agoulnik AI. Relaxin signaling in uterine fibroids. Ann N Y Acad Sci. 1160:374-8. Apr, 2009.

30.  Agoulnik IU, Weigel, NL. Coactivator Selective Regulation of Androgen Receptor Activity. Steroids, 74(8):669-74. Aug, 2009.

31.  Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM, Pereira R, Han HD, Lopez-Berestein G, Klonisch T, Ittmann MM, Sood AK, Agoulnik AI. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer. 17(4):1021-33. Dec, 2010.

32.  Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, Ittmann MM, Weigel NL, Agoulnik IU. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 71(2):572-82. Jan, 2011.

33.  Agoulnik IU, Hodgson MC, Bowden WA, Ittmann MM. INPP4B: the New Kid on the PI3K Block. Oncotarget. Apr. 2011.